Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Acrux ( (AU:ACR) ) has issued an update.
Acrux has announced the commencement of John Warmbrunn as the new CEO and Managing Director, succeeding Michael Kotsanis. The company has launched three new generic topical products in the USA, including Dapsone 7.5% Gel, which is contributing to accelerated revenue growth. The company received short-term RDTI funding from Radium Capital, supporting its transition from a research-focused entity to a commercialized product portfolio. The recent product launches, including Nitroglycerin 0.4% Ointment, have shown promising market traction, and Acrux aims to leverage its FDA-compliant product development capabilities to expand its market presence.
More about Acrux
Acrux Limited is a specialty topical pharmaceuticals development company based in Melbourne, Australia. The company focuses on developing and commercializing topical generic products, with a market focus on the United States and potential international expansion.
Average Trading Volume: 350,843
Technical Sentiment Signal: Sell
Current Market Cap: A$7.37M
See more insights into ACR stock on TipRanks’ Stock Analysis page.